Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Slightly Bearish -18

Q4 Earnings Outperformers: Agilent (NYSE:A) And The Rest Of The ...

🔬 The research tools & consumables subsector supports scientific discoveries across academia, biotech, and pharma through essential laboratory products.

📈 As a group, 10 tracked companies reported satisfactory Q4 results with revenues beating analyst consensus estimates by 1.2%.

⚠️ Despite positive earnings news, the sector's average share prices are down 19.5% since the latest earnings reports.

🧬 Agilent (NYSE:A) reported $1.80 billion in Q4 revenue, up 7% year-on-year but delivering the weakest performance within the tracked group.

💸 Agilent’s stock is down 9.4% since reporting and trades at $112.94 with next-quarter revenue guidance beating expectations.

🧪 Bio-Techne (NASDAQ:TECH) reported flat year-on-year revenues of $295.9 million, outperforming analyst organic revenue estimates by 2%.

📉 Bio-Techne’s stock has fallen 18.4% since reporting and currently trades at $52.72 despite a solid operational quarter.

⚖️ Mettler-Toledo (NYSE:MTD) achieved 8.1% year-on-year revenue growth to $1.13 billion, exceeding analyst expectations by 2.3%.

📉 Mettler-Toledo missed next-quarter revenue and EPS guidance significantly, with its stock down 12.9% since results reporting.

🧬 Revvity (NYSE:RVTY) reported $772.1 million in Q4 revenue, a 5.8% increase that surpassed analyst expectations by 1.1%.

🔍 Revvity provided the weakest full-year guidance update among peers with its stock down 18.3% to $88.86 post-earnings.

🛡️ Sotera Health Company (NASDAQGS:SHC) generated $303.4 million in revenue, up 4.6%, and beat analyst full-year EPS guidance significantly.

🚀 Sotera Health recorded the highest full-year guidance raise among peers with its stock trading at $13.50 after a 22.8% decline.

⏳ The sector faces headwinds including supply chain disruptions, macroeconomic sensitivity, and pricing pressures from budget-conscious institutions.

🤖 Future growth is expected from demand in synthetic biology, personalized medicine, and the rise of AI-driven laboratory solutions.

Bullish Signals
  • The research tools & consumables subsector delivered a satisfactory Q4 with group revenues beating analysts' consensus estimates by 1.2%.
  • Agilent Technologies reported year-over-year revenue growth of 7% to $1.80 billion, meeting analyst expectations.
  • Bio-Techne outperformed analysts' expectations by 2% with revenues of $295.9 million and a solid beat on organic revenue estimates.
  • Mettler-Toledo reported year-over-year revenue growth of 8.1% to $1.13 billion, exceeding analysts' expectations by 2.3%.
  • Revvity achieved strong performance with revenues up 5.8% year over year and surpassed analysts' expectations by 1.1%.
  • Revvity logged full-year revenue guidance slightly topping analysts' expectations and beat organic revenue estimates.
  • Sotera Health Company produced an impressive beat of analysts' full-year EPS guidance estimates and topped revenue expectations.
  • Sotera Health Company pulled off the highest full-year guidance raise among its peers, signaling strong future outlook.
Risk Factors
  • The research tools subsector faces significant headwinds including high R&D investment requirements to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles.
  • Amidst satisfactory Q4 earnings results for the group, share prices have had a rough stretch with the average decline of 19.5% since latest earnings results.
  • Agilent Technologies delivered the weakest performance against analyst estimates of the whole group despite revenue being in line with expectations, leading to its stock down 9.4%.
  • Mettler-Toledo posted significant misses for next quarter's revenue guidance and EPS guidance estimates which caused its stock to fall 12.9% since reporting.
  • Revvity had the weakest full-year guidance update among its peers despite a strong quarterly performance, resulting in its stock down 18.3%.
  • Sotera Health Company saw its stock drop 22.8% from reporting results, indicating market concern despite beating analyst expectations on EPS and revenue guidance.
  • Bio-Techne's flat year-on-year revenue growth outperformed expectations slightly but the market remains unhappy as the stock is down 18.4% since reporting.
Full Analysis
A group of ten research tools and consumables stocks reported Q4 earnings that collectively beat analysts' consensus revenue estimates by 1.2%, though next quarter's guidance remained in line with expectations. Despite the positive financial results, investor sentiment has been tepid, with the average share price of these companies down 19.5% since the latest reporting period. The sector remains subject to ongoing challenges including high R&D costs, pricing pressures from budget-conscious institutions, and sensitivity to macroeconomic conditions affecting research funding cycles. Among the specific performers, Agilent Technologies (NYSE:A) delivered the weakest performance against analyst estimates within the tracked group, with revenues of $1.80 billion rising 7% year on year but failing to beat expectations for next quarter's revenue. The stock has declined 9.4% since reporting and trades at $112.94. Bio-Techne (NASDAQ:TECH) saw revenues flat year on year at $295.9 million, which was an organic revenue beat of 2%, though its shares fell 18.4% to $52.72. Conversely, Mettler-Toledo (NYSE:MTD) reported revenues of $1.13 billion up 8.1%, exceeding expectations by 2.3%, but significantly missed next quarter's revenue and EPS guidance estimates, leading to a 12.9% stock decline from $1,204. Revvity (formerly PerkinElmer) posted revenues of $772.1 million, up 5.8% year on year, surpassing expectations by 1.1% and posting the weakest full-year guidance update among its peers despite beating organic revenue estimates; its stock is down 18.3% to $88.86. Sotera Health Company (NASDAQGS:SHC) achieved a significant beat of 1.2% with revenues of $303.4 million up 4.6% year on year, also pulling off the highest full-year guidance raise among peers, though shares are down 22.8% to $13.50. The article concludes by noting that while AI presents headwinds such as eroding pricing power for software companies, it simultaneously opens new opportunities in laboratories through automation and AI-driven solutions for selling tools and consumables.